Welcome to our dedicated page for Fifty 1 Labs news (Ticker: FITY), a resource for investors and traders seeking the latest updates and insights on Fifty 1 Labs stock.
Fifty 1 Labs, Inc. develops biotechnology and life sciences initiatives centered on peptide products, peptide discovery, AI-enabled research, and clinical development for musculoskeletal health, recovery, and performance. News about FITY commonly covers the company’s transition into peptide biotechnology, its use of artificial intelligence in discovery and research, and program areas involving muscle, tendon, ligament, bone, pain management, injury recovery, and personalized wellness.
Company updates also address capital-structure actions, including the retirement of Series B Preferred Stock to reduce potential common-share dilution, as well as governance, audit, and corporate-status developments. Recent corporate communications have clarified the status of former subsidiary relationships and prior collaboration references while keeping the company’s current focus on peptide therapeutics and wellness-oriented life sciences.
Fifty 1 Labs (OTC:FITY) announced the acquisition of a musculoskeletal recovery product line from MSK Signal, a Canadian biotech company. The all-stock transaction uses Series B Preferred Stock and adds a five-product portfolio spanning injury recovery, rehabilitation, connective tissue support, joint health, and peptide-focused research.
The acquired concepts include an investigational BPC-157 recovery platform, Tendon+ Collagen Recovery, Acute Recover, Surgery Recover Pack, and Joint Matrix. According to Fifty 1 Labs, the deal supports its strategy at the intersection of peptide biotechnology, translational musculoskeletal science, digital health, and evidence-driven product innovation, with potential integration into future telehealth and clinician-guided care models.
Fifty 1 Labs (OTC: FITY) outlined plans for a U.S.-focused telehealth peptide services platform designed as a patient-facing complement to its peptide science and commercialization activities, while remaining separate from investigational clinical-development programs.
The planned model is expected to support digital intake, scheduling of virtual or in‑person consultations, and evaluation by appropriately licensed healthcare professionals, including physicians, nurse practitioners, naturopathic doctors where permitted, and other qualified clinicians. When a peptide therapy is deemed medically appropriate and legally available, prescriptions may be routed to qualified compounding pharmacies for dispensing.
According to the company, potential revenue streams may include monthly memberships, virtual visit fees, care-management services, lab and monitoring coordination, patient-support services, and pharmacy-related service arrangements where allowed. Fifty 1 Labs plans to structure the platform in compliance with federal and state healthcare, telemedicine, pharmacy, privacy, advertising, and professional-practice rules. Launch timing remains dependent on regulatory review, clinician contracting, pharmacy integration, technology development, insurance, state-by-state legal analysis, and financing.
Fifty 1 Labs (OTC: FITY) announced a strategic shift to become a peptide-focused biotechnology and telehealth company centered on peptide science, musculoskeletal health, recovery, and evidence-based product innovation. The evolving strategy combines peptide R&D, AI-enabled discovery workflows, and a planned U.S. telehealth peptide services platform.
Planned R&D may cover candidates such as BPC-157, TB-500, MOTS-c, sermorelin, novel analogues, and delivery concepts, with activities spanning in silico design, pathway mapping, formulation assessment, preclinical planning, and clinical-protocol development for potential Phase I–III studies. In parallel, the company aims to build a telehealth model enabling digital intake, clinical evaluation, and, where permitted, prescriptions for individualized peptide therapies dispensed by compounding pharmacies, under licensed clinical oversight and applicable U.S. regulatory and professional requirements.
The company emphasizes that all peptide candidates and services remain investigational and that there is no assurance any program, telehealth service, partnership, acquisition, financing, or commercialization effort will succeed, generate revenue, or achieve profitability.
Fifty 1 Labs (OTC:FITY) is expanding its biotechnology strategy into peptide discovery and clinical-stage development for musculoskeletal (MSK) health, recovery, and performance. The company plans near-term first-in-human peptide research, AI-enabled discovery, partnerships, and a staged clinical pipeline from Phase I through Phase III.
Corporate action: The company retired 1,748,933 Series B preferred shares, removing potential conversion of ~612,126,550 common shares and materially reducing future dilution.
Fifty 1 Labs (OTCID:FITY) retired 1,748,933 Series B preferred shares on April 14, 2026, permanently eliminating conversion rights for approximately 612,126,550 common shares.
The company used its own funds to repurchase and retire the preferred shares to treasury, aiming to reduce future dilution, strengthen capital structure, and improve the public float for shareholders.
Fifty1 Labs (OTC:FITY) issued a clarification on Jan 5, 2026 confirming that no formal partnership or collaboration ever existed with LUNR Aerospace and that there is no current intent to form one. The release states Mr. Arora resigned as CEO on Dec 1, 2025 after guiding the company through a transition and that Dr Joel Gagnier is the current CEO. Fifty1 Labs confirmed it divested from Fifty1AI Labs Inc on Dec 3, 2025, and says there is no common ownership, management, directors, funding, work overlap, or affiliation between Fifty1 Labs (or its subsidiary) and LUNR Aerospace.
Fifty1 Labs (OTC:FITY) named Dr. Joel Gagnier as Chief Science Officer on October 9, 2025, bolstering its evidence-based AI efforts in personalized wellness, musculoskeletal health, pain management, and perioperative outcomes.
Dr. Gagnier brings academic and industry credentials: ND, MSc, PhD, a postdoctoral fellowship, an associate professorship at Western University, leadership in clinical epidemiology education, >CAD 20 million in secured research funding, >210 peer-reviewed papers, and >300 international lectures. His expertise covers clinical trial methodology, PROMs, meta-analysis, AI/ML integration, regulatory submissions, and product development—skills positioned to strengthen research rigor, regulatory readiness, and investor/partner confidence.
Fifty 1 Labs (OTC: FITY) has signed a Letter of Intent to acquire BioSpark AI Technologies, a Vancouver-based AI innovator specializing in clinical data analysis. The acquisition terms include 25 million common shares contingent upon BioSpark achieving a revenue-based valuation milestone of US$25 million.
The deal encompasses BioSpark's proprietary large language model ensemble technology and key intellectual property, including US Patent Application Publication No. US 20250029734 A1. The companies' previous collaboration has already yielded significant results, including the identification of over 2,000 real-world treatment pathways in drug repurposing initiatives.
This strategic acquisition aims to strengthen Fifty 1 Labs' position in the AI-healthcare market, focusing on drug discovery, personalized medicine, and healthcare optimization.
Fifty 1 Labs (OTC:FITY) has engaged a PCAOB-registered auditing firm to conduct audits of its 2024 and 2025 financial statements, marking a crucial step toward uplisting to the OTCQB® Venture Market. This strategic move aims to enhance the company's market visibility and attract broader investor interest.
The Nevada-based holding company, focused on AI-driven drug repurposing and functional medicine, demonstrates its commitment to transparency and corporate governance through this initiative. Additionally, the company recently published a technical primer on transportability methods in oncology real-world evidence in the Journal of Comparative Effectiveness Research, highlighting its expertise in AI and oncology data analysis.
Fifty1 Labs (OTC:FITY) has published a groundbreaking technical framework for enhancing oncology real-world evidence (RWE) through AI-driven transportability methods. The publication, authored by CTO Alind Gupta and CEO Paul Arora in the Journal of Comparative Effectiveness Research, positions the company in the rapidly expanding RWE market.
The framework enables cross-border application of oncology data, particularly valuable for rare diseases and underserved regions. The company's AI platform integrates advanced analytics including matching, weighting, and standardization techniques to enhance data reliability for health technology assessments.
The oncology RWE market is projected to grow from $789 million in 2024 to $3.51 billion by 2035, with a 14.7% CAGR. The broader RWE solutions market is expected to reach $48 billion by 2032, presenting significant growth opportunities for Fifty1 Labs.